DE60325692D1 - Pyrimidinonen als virale polymerase inhibitoren - Google Patents

Pyrimidinonen als virale polymerase inhibitoren

Info

Publication number
DE60325692D1
DE60325692D1 DE60325692T DE60325692T DE60325692D1 DE 60325692 D1 DE60325692 D1 DE 60325692D1 DE 60325692 T DE60325692 T DE 60325692T DE 60325692 T DE60325692 T DE 60325692T DE 60325692 D1 DE60325692 D1 DE 60325692D1
Authority
DE
Germany
Prior art keywords
sup
pyrimidinones
polymerase inhibitors
viral polymerase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325692T
Other languages
German (de)
English (en)
Inventor
Salvatore Avolio
Stefania Colarusso
Immacolata Conte
Steven Harper
Uwe Koch
Savina Malancona
Victor Giulio Matassa
Frank Narjes
Alessia Petrocchi
Vincenzo Summa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Application granted granted Critical
Publication of DE60325692D1 publication Critical patent/DE60325692D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60325692T 2002-01-18 2003-01-15 Pyrimidinonen als virale polymerase inhibitoren Expired - Lifetime DE60325692D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201179.9A GB0201179D0 (en) 2002-01-18 2002-01-18 Therapeutic agents
PCT/GB2003/000124 WO2003062211A1 (en) 2002-01-18 2003-01-15 Pyrimidinone viral polymerase inhibitors

Publications (1)

Publication Number Publication Date
DE60325692D1 true DE60325692D1 (de) 2009-02-26

Family

ID=9929352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325692T Expired - Lifetime DE60325692D1 (de) 2002-01-18 2003-01-15 Pyrimidinonen als virale polymerase inhibitoren

Country Status (8)

Country Link
US (1) US20050130997A1 (https=)
EP (1) EP1470113B1 (https=)
JP (1) JP4498745B2 (https=)
AT (1) ATE420078T1 (https=)
CA (1) CA2473508A1 (https=)
DE (1) DE60325692D1 (https=)
GB (1) GB0201179D0 (https=)
WO (1) WO2003062211A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
WO2005016384A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
CN102911161A (zh) 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
BRPI0614205A2 (pt) 2005-08-01 2016-11-22 Merck & Co Inc composto, composição farmacêutica, e, uso de composto
US7939537B2 (en) * 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP2010507656A (ja) 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド Ｈｃｖｎｓ３プロテアーゼ阻害剤
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
WO2008057209A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
AU2007318164B2 (en) 2006-10-27 2013-02-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CN103224506A (zh) 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 抗病毒的吲哚
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2142215B1 (en) 2007-05-04 2012-03-07 Vertex Pharmceuticals Incorporated Combination therapy for the treatment of hcv infection
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
CA2693997C (en) * 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
PT2540350E (pt) 2008-07-22 2014-08-27 Merck Sharp & Dohme Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
US8450363B2 (en) 2009-02-06 2013-05-28 Elan Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
MX2011010047A (es) * 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
MX2013001273A (es) 2010-08-13 2013-04-10 Hoffmann La Roche Compuestos heterociclicos antivirales.
US9328075B2 (en) * 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
DE19817265A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
CA2343522A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase

Also Published As

Publication number Publication date
JP4498745B2 (ja) 2010-07-07
ATE420078T1 (de) 2009-01-15
US20050130997A1 (en) 2005-06-16
WO2003062211A1 (en) 2003-07-31
EP1470113B1 (en) 2009-01-07
GB0201179D0 (en) 2002-03-06
JP2005524627A (ja) 2005-08-18
EP1470113A1 (en) 2004-10-27
CA2473508A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
DE60325692D1 (de) Pyrimidinonen als virale polymerase inhibitoren
DE60140127D1 (en) Dihydroxypyrimidin-carbonsäuren als virale polymerase inhibitoren
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
CY1112108T1 (el) Αναστολεις ιου ηπατιτιδας c
BRPI0410456B8 (pt) compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
EA200700038A1 (ru) Ингибиторы вирусных полимераз
AU2003240488A1 (en) Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
WO2005054430A3 (en) Hepatitis c virus inhibitors
IS8448A (is) Lifrarbólgu C-veirutálmar
NZ514403A (en) Fused-ring compounds and use thereof as drugs
GT200200117A (es) Derivados de nucleosidos
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
ATE474827T1 (de) Hcv-replikationshemmer
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
DE69909756D1 (de) Antivirale pyrimidinderivate
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE69925918D1 (de) Diketosäure-derivate als hemmstoffe von polymerasen
ATE486889T1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
DE60101223D1 (de) Antivirale pyrimidin nucleoside derivate
MA32006B1 (fr) Inhibiteurs de polymerase virale
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
DOP2003000641A (es) Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции

Legal Events

Date Code Title Description
8364 No opposition during term of opposition